Circulating levels of brodalumab tied to therapy outcomes in psoriasis patients: Study

Denmark: Circulating brodalumab level is a factor associated with clinical treatment response in patients with psoriasis, states case series study results published in JAMA Dermatology. Monitoring levels of circulating brodalumab in psoriasis patients may help clinical decision-making towards the prevention of ineffective therapy, the study suggests.

Psoriasis is a serious global problem, affecting at least 100 million individuals of all ages, and in all countries. With recent advances, many possible treatment modalities in psoriasis management are available but estimating the ideal treatment choice for each patient is a challenge. There are no validated, clinically useful biomarkers and so treatment modalities are generally applied on a trial-and-error basis. Brodalumab, a human monoclonal antibody to the interleukin-17A receptor, which acts as an immunosuppressant may be considered as first-line therapy in Psoriasis and also as rescue therapy in patients refractory to treatment.

A multicenter case series study was performed by Christian Enevold, Copenhagen University Hospital, Denmark, and colleagues to assess whether brodalumab levels are associated with clinical response, as measured by reductions in Psoriasis Area and Severity Index (PASI), and can be used as a marker of long term response.

They measured trough levels of circulating brodalumab and antidrug antibodies in 20 consecutive patients with prior failure to anti–IL-17A therapy, who had baseline PASI score of 6 or higher and had not received concomitant systemic treatment for psoriasis,